F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy.

Aleksandra I Adamovich, Amanda Ewart Toland, Jeffrey D Parvin

Abstract readComment

In one paragraph

Article in Molecular cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

0.4field-weighted citation impact, top 35% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.PloS one · 2021
Article
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.Cancers · 2020
Review
Overexpression of FBXO17 Promotes the Proliferation, Migration and Invasion of Glioma Cells Through the Akt/GSK-3β/Snail Pathway.Cell transplantation
Article

4 · The record

Corrections and comments

Comment on
The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.2019

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Aleksandra I AdamovichDepartment of Biomedical Informatics, The Ohio State University and The OSU Comprehensive Cancer Center, Columbus, OH, USA.

Amanda Ewart TolandDepartment of Cancer Biology and Genetics, The Ohio State University and The OSU Comprehensive Cancer Center, Columbus, OH, USA.

Jeffrey D ParvinDepartment of Biomedical Informatics, The Ohio State University and The OSU Comprehensive Cancer Center, Columbus, OH, USA. Electronic address: jeffrey.parvin@osumc.edu.

The Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PARP inhibitor (PARPi) therapy targets BRCA1/2 mutant tumor cells, but acquired resistance limits its effectiveness. In this issue of Molecular Cell, Marzio et al. (2019) identify a novel mechanism of resistance to PARPi through regulation of RAD51 protein stability via an SCF ubiquitin ligase dependent on EMI1.

Indexed as

Poly(ADP-ribose) Polymerase InhibitorsTriple Negative Breast NeoplasmsDrug Resistance, NeoplasmF-Box ProteinsHumansRad51 RecombinaseF-Box ProteinsPoly(ADP-ribose) Polymerase InhibitorsRad51 Recombinase

Identifiers

PMID30658107

DOI10.1016/j.molcel.2018.12.019

OpenAlexW2910609717

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.